Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04763499
Other study ID # 1567320
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date December 1, 2021
Est. completion date December 31, 2022

Study information

Verified date May 2023
Source University of California, Davis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall objective of this proposed trial is to examine the vascular protective effects provided by the daily consumption of 39g of freeze dried strawberry powder (FDSP) for four weeks. The study population will be older men (60-80 years of age).


Description:

The proposed project will determine the influence of short-term FDSP intake on microvascular function in older men (60-80 years of age). The Framingham reactive hyperemia index (fRHI) will be used as a measure of microvascular function, and will be measured using peripheral arterial tonometry (PAT; EndoPAT200). Secondary outcomes will assess circulating levels of nitrate and nitrite, insulin-like growth factor (IGF), inflammatory cytokines, NADPH oxidase, platelet aggregation, plasma lipids and blood pressure. This suite of markers will provide insight on physiological outcomes and risk factors associated with CVD development, and the metabolic and signaling pathways that influence them. To accomplish the above, after a 4 week run in period of no powder intake, twenty men (60-80 years of age) will be randomly assigned to consume 39 g of FDSP or a control powder for four weeks in a randomized, double-blind, controlled crossover study. This study design will compare the short-term (four week) response of FDSP intake to an isocaloric control powder that provides no polyphenols, as well as to their habitual diet where no powder was consumed.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 60 Years to 80 Years
Eligibility Inclusion Criteria: - Subject is willing and able to comply with the study protocols. - Subject is willing to participate in all study procedures - BMI 25.0 - 35 kg/m2 Exclusion Criteria: - BMI = 35 kg/m2 - Visit 1 Reactive Hyperemia Index (RHI; EndoPAT 2000) = 2.8 - Dislike or allergy strawberries - Self-reported use of daily anticoagulation agents including aspirin, NSAIDs - Prescription medications other than on a 6 month self-reported stable dose of medications for lipid lowering and/or hypertension. - Vegan, Vegetarians, food faddists or those consuming a non-traditional diet - Fruit consumption = 3 cups/day - Regular consumption of strawberries (2-3 servings/week) - Vegetable consumption = 4 cups/day - Coffee/tea = 3 cups/day - Dark chocolate = 3 oz/day - Self-reported restriction of physical activity due to a chronic health condition - Self-reported chronic/routine high intensity exercise - Self-reported diabetes - Blood pressure = 140/90 mm Hg - Self-reported renal or liver disease - Self-reported heart disease, which includes cardiovascular events and stroke - Peripheral artery disease Raynaud's syndrome or disease - Inability to properly place or wear the PAT probes or abnormal measurements on pre- screening PAT - Abnormal Metabolic or CBC panels (laboratory values outside the reference range) if determined to be clinically significant by the study physician. - Self-reported cancer within past 5 years - Self-reported malabsorption - Supplement use other than a general formula of vitamins and minerals that meet the RDA - Not willing to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements a month prior to study enrollment. - Indications of substance or alcohol abuse within the last 3 years - Cannabis use - Current enrollee in a clinical research study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
freeze dried strawberry powder
approximately 24 strawberries that have been freeze dried into a powder

Locations

Country Name City State
United States University of California, Davis; Department of Nutrition Davis California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Davis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other blood pressure systolic and diastolic blood pressure 4 weeks
Other plasma lipids clinical lipid panel 4 weeks
Primary Framingham Reactive Hyperemia Index (fRHI) fRHI as a measure of microvascular function will be measured by peripheral arterial tonometry (PAT). 4 weeks
Secondary platelet aggregation optimal platelet aggregometry using collagen and adp as agonist 4 weeks
Secondary Th17 cytokines TH17 Luminex panel: Interleukin (IL)-1b, IL-4, IL-6, IL-10, IL-17a, IL-21, IL-22, IL-23, IL-31, IL-33, IFNgamma, TNFalpha, IL-17f. 4 weeks
Secondary insulin like growth factor (IGF) and binding proteins (IGFBP) Luminex panel: IGF-1, -2 and IGFBP 1-7 4 weeks
Secondary Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase soluble form marker of oxidative stress 4 weeks
Secondary total nitrate and nitrite plasma total nitrate and nitrite 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Active, not recruiting NCT03962855 - Thromboxane Receptor Antagonist to Improve Endothelial Cell Function Phase 2
Recruiting NCT05545865 - Chardonnay Marc and Vascular Response N/A
Active, not recruiting NCT05353790 - Dietary Exchanges With Avocado and Mango in Pre-diabetes N/A
Completed NCT05221905 - Effects of Inorganic Nitrate and Intensity of Exercise on Cardiovascular Health in Post-Menopausal Females Phase 1
Active, not recruiting NCT04596501 - Exercise Training and Thrombotic Risk in Post-menopausal Women N/A
Recruiting NCT06145087 - Effects of a Supplement to Target Ageing Mechanisms on Vascular Function (STAMINA) N/A
Recruiting NCT05647876 - A Longitudinal Study to Identify Mechanisms of Menopause on Cardiovascular Disease Risk
Completed NCT05798182 - Ultrasound Markers of Systemic Inflammation